OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.

Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.

The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain.

The company was incorporated in 2007 and is headquartered in London, the United Kingdom.